Matthew D. Galsky

Active 2005–2026

194
Papers
29,795
Citations
80
h-index
177
i10-index

Citations

Citations per year for Matthew D. Galsky1990: 2 citations1991: 1 citations1996: 1 citations1997: 2 citations1999: 2 citations2000: 3 citations2001: 2 citations2002: 3 citations2003: 3 citations2004: 3 citations2005: 8 citations2006: 7 citations2007: 10 citations2008: 14 citations2009: 15 citations2010: 16 citations2011: 18 citations2012: 21 citations2013: 56 citations2014: 62 citations2015: 62 citations2016: 138 citations2017: 317 citations2018: 340 citations2019: 944 citations2020: 1,442 citations2021: 1,677 citations2022: 1,213 citations2023: 948 citations2024: 1,602 citations2025: 847 citations2026: 43 citations1992–1995: no citations, so these years are not shown1998: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,994 citing papers, 23.7% of this breakdownChina: 1,820 citing papers, 14.4% of this breakdownUnited Kingdom: 704 citing papers, 5.6% of this breakdownItaly: 701 citing papers, 5.6% of this breakdownFrance: 569 citing papers, 4.5% of this breakdownGermany: 552 citing papers, 4.4% of this breakdownSpain: 484 citing papers, 3.8% of this breakdownCanada: 436 citing papers, 3.5% of this breakdownJapan: 382 citing papers, 3% of this breakdownNetherlands: 327 citing papers, 2.6% of this breakdownSwitzerland: 266 citing papers, 2.1% of this breakdownAustralia: 254 citing papers, 2% of this breakdown
0%23.7%Other 24.8%

Fields

  • Medicine74.7%
  • Biochemistry, Genetics and Molecular Biology16.4%
  • Immunology and Microbiology4%
  • Engineering0.9%
  • Psychology0.7%
  • Materials Science0.6%
  • Other2.7%

Topics

  • Cancer Immunotherapy and Biomarkers11.5%
  • Bladder and Urothelial Cancer Treatments9.4%
  • Urinary and Genital Oncology Studies4.1%
  • Ferroptosis and cancer prognosis3.3%
  • Immunotherapy and Immune Responses3.2%
  • COVID-19 and healthcare impacts2.5%
  • Other66%

Coauthors

All papers

Open in search
  1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Dreicer - The Lancet 2016 cited by 3,714

  2. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 1,031

  3. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin - The Lancet 2016 cited by 2,211

  4. Treatment of muscle‐invasive and advanced bladder cancer in 2020

    Authors: , , - CA A Cancer Journal for Clinicians 2020 cited by 1,133

  5. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 462

  6. Bladder cancer

    Authors: , , , , , , - Nature Reviews Disease Primers 2023 cited by 480

  7. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2020 cited by 787

  8. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 626

  9. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 cited by 1,744

  10. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial

    Authors: , , , , , , , , , , , , , , - Cancer Cell 2020 cited by 393

  11. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli and 127 more - The Lancet Oncology 2020 cited by 498

  12. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

    Authors: , , , , , , , , , , - Journal of Clinical Oncology 2011 cited by 688

  13. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 322

  14. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity

    Authors: , , , , , - The Oncologist 2017 cited by 400

  15. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Reza Mehrazin, Nina Bhardwaj, Menggang Yu, Qianqian Zhao, Seunghee Kim‐Schulze, Robert Sebra, Jun Zhu, Sacha Gnjatic, John P. Sfakianos, Sumanta K. Pal - Nature Medicine 2023 cited by 133

  16. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 100

  17. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors

    Authors: , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2022 cited by 100

  18. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Sebra, Doug Palmer, Eleanor Clancy‐Thompson, Scott A. Hammond, Alice O. Kamphorst, Karl‐Johan Malmberg, Emanuela Marcenaro, Pedro Romero, Rachel Brody, Mathias Viard, Yuko Yuki, Maureen P. Martin, Mary Carrington, Reza Mehrazin, Peter Wiklund, Ira Mellman, Sanjeev Mariathasan, Jun Zhu, Matthew D. Galsky, Nina Bhardwaj, Amir Horowitz - Cancer Cell 2022 cited by 127

  19. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Communications 2018 cited by 331

  20. What Is the Significance of Variant Histology in Urothelial Carcinoma?

    Authors: , , , , , , , , , , , - European Urology Focus 2019 cited by 244

  21. Selective PP2A Enhancement through Biased Heterotrimer Stabilization

    Authors: , , , , , , , , , , , , , , , , , , - Cell 2020 cited by 183

  22. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anthony P. Gulati, Shilpa Gupta, Navid Hafez, Þorvarður R. Hálfdánarson, Jessica E. Hawley, Emily Hsu, Anup Kasi, Ali Raza Khaki, Christopher A. Lemmon, Colleen Lewis, Barbara Logan, Tyler Masters, Rana R. McKay, Ruben A. Mesa, Alicia K. Morgans, Mary F. Mulcahy, Orestis A. Panagiotou, Prakash Peddi, Nathan A. Pennell, Kerry L. Reynolds, L Rosen, Rachel Rosovsky, Mary Salazar, Andrew Schmidt, Sumit Shah, Justin Shaya, John A. Steinharter, Keith Stockerl‐Goldstein, Suki Subbiah, Donald C. Vinh, Firas Wehbe, Lisa B. Weissmann, Julie Wu, Elizabeth Wulff‐Burchfield, Zhuoer Xie, Albert C. Yeh, Peter Paul Yu, Alice Y. Zhou, Leyre Zubiri, Sanjay Mishra, Gary H. Lyman, Brian I. Rini, Jeremy L. Warner, Maheen Z. Abidi, Jared D. Acoba, Neeraj Agarwal, Syed A. Ahmad, Archana Ajmera, Jessica K. Altman, Anne H. Angevine, Nilo Azad, Michael Bär, Aditya Bardia, Jill S. Barnholtz‐Sloan, Briana Barrow, Babar Bashir, Rimma Belenkaya, Stephanie Berg, Eric Bernicker, Christine M. Bestvina, Rohit Bishnoi, Genevieve M. Boland, Mark Bonnen, Gabrielle Bouchard, Daniel W. Bowles, Fiona Busser, Angelo Cabal, Paolo F. Caimi, Theresa M. Carducci, Carla Casulo and 136 more - The Lancet 2020 cited by 1,802

  23. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

    Authors: , , , , , , , , , , , , , , , - Science Translational Medicine 2020 cited by 128

  24. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

    Authors: , , , , , , , , , , - The Lancet Oncology 2011 cited by 345